葡萄膜黑色素瘤生存预后相关lncRNA的初步筛选及相关性分析

doi:10.3760/cma.j.cn115909-20210513-00193

Abstract
Figure/Table
References (32)
Related Citation (1)

Download: PDF (1922 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Guide

Abstract Objective: To construct a competing endogenous RNA (ceRNA) network of lncRNA-miRNA-mRNA, and to screen the long non-coding RNA (lncRNA) associated with the survival prognosis of uveal melanoma (UM). Methods: In this study, the expression data set of lncRNA was screened from the Tumor Genome Atlas Database through disease prognosis correlation analysis and a subcellular localization search of lncRNA using bioinformatics methods. Target microRNAs (miRNAs) corresponding to lncRNAs were found by the mircode database, targetscan database, and common miRNAs associated with UM prognosis were screened out by Venn analysis. The common miRNA-mRNA was screened from multiple databases simultaneously. Through KEGG enrichment and lncRNA-miRNA-mRNA network visualization, candidate lncRNAs related to the survival prognosis of UM were finally identified. Results: In the prediction of downstream target miRNAs and the functional genes of lncRNAs, 630 pairs of candidate miRNA-mRNA were identified. Based on the mechanism of gene expression regulation by ceRNAs, 9 lncRNAs that might play the role of ceRNAs were screened out. KEGG analysis showed that the downstream regulatory genes of lncRNAs were mainly enriched in the signaling pathways involved in the pathological process of tumors. SHNG6 may regulate miRNAs such as has-miR-214-5p, has-miR-214-3p, has-miR-let-7b-5p, and has-miR-let-7c-3p, the regulators of downstream functional genes BAX, IGF1R, KRAS, PIK3R1, PDGFD and so on. Conclusions: Through the mechanism of ceRNAs, lncRNAs regulate the expression of a series of oncogenes involved in tumor genesis and development, and affect the prognosis and treatment of UM. lncRNAs such as SHNG6 and LINC01278 may play an important role in its occurrence, development, migration and invasion.

Key words： uveal melanoma long non-coding RNA competing endogenous RNA

Received: 13 May 2021

PACS:

Fund:

Corresponding Authors: Xiangxiang Lin,the First Affiliated Hospital of Wenzhou Medical University,Zhejiang Provincial Key Laboratory of Aging and Neurological Disorder Research, Wenzhou 325015,China (Email:xiangxianglin003@163.com)

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Huiping Shang1
	Xiangxiang Lin2

Cite this article:

Huiping Shang1,Xiangxiang Lin2. Preliminary Screening and Analysis of Survival Prognostic lncRNA in Uveal Melanoma[J]. Chinese Journal of Optometry Ophthalmology and Visual science, 2022, 24(3): 208-215.

URL:

https://www.cjoovs.com/EN/10.3760/cma.j.cn115909-20210513-00193 OR https://www.cjoovs.com/EN/Y2022/V24/I3/208

[1]	Smit KN, Jager MJ, de Klein A, et al. Uveal melanoma: towards a molecular understanding. Prog Retin Eye Res, 2020, 75:100800. DOI: 10.1016/j.preteyeres.2019.100800.
[2]	中国医药教育协会眼科专业委员会, 中华医学会眼科学分会眼整形眼眶病学组,中国抗癌协会眼肿瘤专业委员会.中国葡萄膜黑色素瘤诊疗专家共识(2021年). 中华眼科杂志, 2021, 57(12): 886-897. DOI: 10.3760/cma.j.cn112142-20210926-00452.
[3]	Ghazawi FM, Darwich R, Le M,et al. Uveal melanoma incidence trends in Canada: a national comprehensive population-based study. Br J Ophthalmol, 2019, 103(12): 1872- 1876. DOI: 10.1136/bjophthalmol-2018-312966.
[4]	Xu Y, Lou L, Wang Y, et al.Epidemiological Study of Uveal Melanoma from US Surveillance, Epidemiology, and End Results Program (2010-2015). J Ophthalmol, 2020, 2020:3614039. DOI: 10.1155/2020/3614039.
[5]	Souto EB, Zielinska A, Luis M, et al. Uveal melanoma: physiopathology and new in situ-specific therapies. Cancer Chemother Pharmacol, 2019, 84(1): 15-32. DOI: 10.1007/ s00280-019-03860-z.
[6]	Singh MK, Singh L, Chosdol K, et al.Differential expression of p52 and RelB proteins in the metastatic and non-metastatic groups of uveal melanoma with patient outcome. J Cancer Res Clin Oncol, 2019, 145(12): 2969-2982. DOI: 10.1007/s00432- 019-03052-5.
[7]	Bagger M, Smidt-Nielsen I, Andersen MK, et al.Long-Term Metastatic Risk after Biopsy of Posterior Uveal Melanoma. Ophthalmology, 2018, 125(12): 1969-1976. DOI: 10.1016/ j.ophtha.2018.03.047.
[8]	Field MG, Decatur CL, Kurtenbach S, et al. PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma. Clin Cancer Res, 2016, 22(5): 1234-1242. DOI: 10.1158/1078-0432. Ccr-15-2071.
[9]	Koopmans AE, Vaarwater J, Paridaens D, et al.Patient survival in uveal melanoma is not affected by oncogenic mutations in GNAQ and GNA11. Br J Cancer, 2013, 109(2): 493-496. DOI: 10.1038/bjc.2013.299.
[10]	Chattopadhyay C, Kim DW, Gombos DS, et al. Uveal melanoma: from diagnosis to treatment and the science in between.Cancer, 2016, 122(15): 2299-2312. DOI: 10.1002/cncr.29727.
[11]	Wan Q, Tang J, Han Y, et al. Co-expression modules construction by WGCNA and identify potential prognostic markers of uveal melanoma. Exp Eye Res, 2018, 166:13-20. DOI: 10.1016/ j.exer.2017.10.007.
[12]	赵云萍, 金珊珊, 刘琦, 等. DZNep靶向EZH2抑制葡萄膜黑色素瘤细胞增殖.中华眼视光学与视觉科学杂志. 2020, 22(7): 492-499. DOI: 10.3760/cma.j.cn115909-20190426-00124.
[13]	Johansson P, Aoude LG, Wadt K, et al.Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4.Oncotarget, 2016, 7(4): 4624-4631. DOI: 10.18632/oncotarget.6614.
[14]	Moore AR, Ceraudo E, Sher JJ, et al. Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma. Nat Genet, 2016, 48(6): 675-680. DOI: 10.1038/ ng.3549.
[15]	Turunen JA, Markkinen S, Wilska R, et al. BAP1 Germline Mutations in Finnish Patients with Uveal Melanoma.Ophthalmology, 2016, 123(5): 1112-1117. DOI: 10.1016/ j.ophtha.2016.01.008.
[16]	Cebulla CM, Binkley EM, Pilarski R, et al. Analysis of BAP1 Germline Gene Mutation in Young Uveal Melanoma Patients.Ophthalmic Genet, 2015, 36(2): 126-131. DOI: 10.3109/13816810.2015.1010734.
[17]	Maerker DA, Zeschnigk M, Nelles J, et al. BAP1 germline mutation in two first grade family members with uveal melanoma.Br J Ophthalmol, 2014, 98(2): 224-227. DOI: 10.1136/bjophthalmol-2013-303814.
[18]	Coupland SE, Lake SL, Zeschnigk M, et al. Molecular pathology of uveal melanoma. Eye (Lond), 2013, 27(2): 230- 242. DOI: 10.1038/eye.2012.255.
[19]	Ewens KG, Kanetsky PA, Richards-Yutz J, et al. Chromosome 3 status combined with BAP1 and EIF1AX mutation profiles are associated with metastasis in uveal melanoma.Invest Ophthalmol Vis Sci, 2014, 55(8): 5160-5167. DOI: 10.1167/ iovs.14-14550.
[20]	李洋, 冯宇, 刘月明, 等.BAP1、 FOXO3 和 ITPR2 基因表达变化与葡萄膜黑色素瘤转移和预后关联分析. 中华实验眼科杂志. 2021, 39(8): 700-707. DOI: 10.3760/cma. j.cn115989-20200714-00495.
[21]	Joshi MRajender S. Long non-coding RNAs (lncRNAs) in spermatogenesis and male infertility. Reprod Biol Endocrinol, 2020, 18(1): 103. DOI: 10.1186/s12958-020-00660-6.
[22]	Panni S, Lovering RC, Porras P, et al. Non-coding RNA regulatory networks. Biochim Biophys Acta Gene Regul Mech, 2020, 1863(6): 194417. DOI: 10.1016/j.bbagrm.2019.194417.
[23]	Yu X, Zheng H, Tse G, et al.Long non-coding RNAs in melanoma. Cell Prolif, 2018, 51(4): e12457. DOI: 10.1111/cpr.12457.
[24]	Huarte M. The emerging role of lncRNAs in cancer. Nat Med, 2015, 21(11): 1253-1261. DOI: 10.1038/nm.3981.
[25]	Li MX, Wang HY, Yuan CH, et al.KLHDC7B-DT aggravates pancreatic ductal adenocarcinoma development via inducing cross-talk between cancer cells and macrophages. Clin Sci (Lond), 2021, 135(4): 629-649. DOI: 10.1042/cs20201259.
[26]	Huang GZ, Wu QQ, Zheng ZN, et al. Identification of Candidate Biomarkers and Analysis of Prognostic Values in Oral Squamous Cell Carcinoma. Front Oncol, 2019, 9:1054. DOI: 10.3389/ fonc.2019.01054.
[27]	Zheng J, Huang X, Tan W, et al.Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation.Nat Genet, 2016, 48(7): 747-757. DOI: 10.1038/ng.3568.
[28]	Yu T, Zhao Y, Hu Z, et al. MetaLnc9 Facilitates Lung Cancer Metastasis via a PGK1-Activated AKT/mTOR Pathway. Cancer Res, 2017, 77(21): 5782-5794. DOI: 10.1158/0008-5472.Can- 17-0671.
[29]	Fan X, Song J, Zhao Z, et al. Piplartine suppresses proliferation and invasion of hepatocellular carcinoma by LINC01391- modulated Wnt/β-catenin pathway inactivation through ICAT. Cancer Lett, 2019, 460:119-127. DOI: 10.1016/ j.canlet.2019.06.008.
[30]	Xu M, Chen X, Lin K, et al. lncRNA SNHG6 regulates EZH2 expression by sponging miR-26a/b and miR-214 in colorectal cancer. J Hematol Oncol, 2019, 12(1): 3. DOI: 10.1186/s13045- 018-0690-5.
[31]	Zhang Y, An J, Pei Y. LncRNA SNHG6 promotes LMO3 expression by sponging miR-543 in glioma. Mol Cell Biochem, 2020, 472(1-2): 9-17. DOI: 10.1007/s11010-020-03772-0.
[32]	Chen S, Xie C, Hu X. lncRNA SNHG6 functions as a ceRNA to up-regulate c-Myc expression via sponging let-7c-5p in hepatocellular carcinoma.Biochem Biophys Res Commun, 2019, 519(4): 901-908. DOI: 10.1016/j.bbrc.2019.09.091.，